Position in ATYR
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$68,980
-$73,499 QoQ
Shares Held
88,436
-51.4% QoQ
Ownership
0.090%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ATYR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026VICTORY CAPITAL MANAGEMENT INC holds $2,531,634,647 across 158 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,173,152 | $1,079,469,792 | |
| 2 | RPRX |
Royalty Pharma plc
|
3,682,932 | $206,501,997 | |
| 3 | INCY |
Incyte Corp
|
1,480,342 | $167,811,569 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
686,719 | $165,478,677 | |
| 5 | LGND |
Ligand Pharmaceuticals Inc
|
253,764 | $80,212,262 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
126,343 | $78,779,914 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
172,842 | $52,030,627 | |
| 8 | BNTX |
BioNTech SE
|
539,787 | $50,227,180 |
All Filings in ATYR
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $68,980 | 88,436 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $142,479 | 181,966 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $139,018 | 192,813 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $52,028 | 10,262 | Shares | Sole | 2025-08-13 | |
| 2024-12-31 | $36,699 | 10,138 | Shares | Sole | 2025-02-06 | |
| 2020-03-31 | $3,642 | 1,301 | Shares | Sole | 2020-05-04 | |
| No filing history on record for this holder in this stock. | ||||||